Pfizer's Diflucan (fluconazole) currently dominates the antifungals market, thanks to a good safety profile, relatively few drug-drug interactions, interchangeable oral and intravenous formulations, and a highly successful marketing campaign. As generic competition erodes fluconazole sales, beginning in 2004, Pfizer will try to maintain market position with its next-generation drug, while Schering-Plough and Bristol- Myers Squibb strive to gain market share with their novel therapeutics. Fungal Opportunistic Infections in HIV, a new report from the Decision Resources, Inc. Pharmacor service, provides an analysis for companies competing or looking to compete in the market.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"Pfizer will attempt to shift usage to voriconazole," says Julia Bradsher, Decision Resources' therapeutic area director for infectious disease. "This market will be increasingly competitive as Schering-Plough's posaconazole and Bristol-Myers Squibb's ravuconazole vie for marketshare, as well as pressure from health care authorities and managed care insurers who favor the generic version of fluconazole," Bradsher adds. Posaconazole's once-daily dosing and favorable side-effect profile could create a valuable niche for Schering- Plough in antifungal prophylaxis. Ravuconazole will enter a highly saturated and competitive environment, but its long half-life may be an advantage in future marketing campaigns if it translates into a shorter course of therapy.

  Fungal Opportunistic Infections in HIV provides the following:    -- An overview of the etiology and pathophysiology of key HIV      opportunistic fungal infections.   -- Patient populations of oropharyngeal candidiasis, esophageal      candidiasis, and cryptococcosis in the seven major pharmaceutical      markets (the United States, France, Germany, Italy, Spain, the United      Kingdom, and Japan).   -- A survey of diagnosis and treatment practices in each of these markets.   -- An analysis of unmet needs in the treatment of fungal opportunistic      infections in HIV.   -- An evaluation of current and emerging drugs.  

To generate this report, Decision Resources interviewed thought-leading clinicians and researchers in each market and used a variety of drug audit data (e.g., IMS Sales, Scott-Levin), analyst reports, publications, and conference reports.

To order your copy of Fungal Opportunistic Infections in HIV call Frank Sama at 781-296-2553 or email sama@dresources.com.

Fungal Opportunistic Infections in HIV is part of the Infectious Disease portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.

   Contact:    Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or    sama@dresources.com.    In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone),    +32.2.351.2347 (fax), or fbidart@decisionresources.be.    In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone),    +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp. 

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X51466558

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,
sama@dresources.com

Introduction of Bextra (valdecoxib) Places Pharmacia in Driver's Seat of Lucrative COX-2 Inhibitor Market, According to a Decision Resources' Study

View Now